| Revenue growth | Consolidated Q4 revenue up 22%; full year FY26 up 7%. |
|---|---|
| Margins | Improvement supported by favorable product mix and operational discipline. |
| Order book | Supplied 6.3 crore PPR doses in Q4 under national program. |
| Demand visibility | Strong for biologicals; Animal Health recovery expected following tender delays. |
| Management confidence | Confident in long-term results from consolidation and capacity expansion initiatives. |
Growth
Q4 revenue grew 22%; Standalone PAT up 174%. FY26 consolidated revenue rose 7%, PAT nearly doubled.
Outlook
Focus on 50-50 revenue mix between Poultry and Animal Health; ramp-up of BSL-3 and Fill-Finish facilities.
Risks
Tender-led business timing volatility, rising raw material costs, and geopolitical supply chain disruptions.
Earnings Call filed with BSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,157.00
- Market cap
- ₹1,835 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.5×Sector 47.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences Annual General Meeting
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Other Announcement
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.